CareDx (CDNA, ≈$1.0B mkt cap) is the leading provider of donor-derived cell-free DNA surveillance testing for kidney/heart/lung transplant patients. The Q1 2026 10-Q (filed April 28, 2026) brought three structural events in one quarter — first GAAP operating profit in company history, a $170M divestiture of the lab products business to Eurobio Scientific, and a same-day $160M+earnout acquisition of Naveris (HPV ctDNA cancer MRD). Twenty-five days earlier the last leg of a five-year regulatory overhang cleared (qui tam voluntarily dismissed April 23). Meanwhile MolDX/Noridian's draft LCD on bundled-payment surveillance limitations has a ~July 2026 finalization deadline and threatens 74% of testing revenue. Two structural shifts and one binary, all converging in the same 60-90 day window.

What the filing says

First GAAP profit. Q1 2026 operating income $1.2M, net income $2.8M (vs operating loss -$13.4M Q1 2025). OCF flipped from -$26.6M to +$4.3M. Revenue $117.7M (+39% YoY), testing services $91.4M (+48%), volume +17%. Testing gross margin 81.3%, +570bps vs Q1 2025.

Revenue quality caveat. Q1 2026 testing services includes $17.7M of prior-period revenue catch-up (vs -$1.1M in Q1 2025). Organic current-period testing revenue ≈$77M (+24% organic). Average revenue per test of ≈$1,660 is inflated; organic closer to ≈$1,400. Whether the catch-up recurs at material scale defines Q2.

Strategic reshape (April subsequent events).

• April 15 — agreed to sell CareDx AB (Swedish subsidiary) + kitted lab products to Eurobio Scientific for $170M cash. Lab products was ≈$10M/quarter at 53% gross margin, declining -4% YoY — drag on blended margins. Post-divestiture, CDNA is pure-play transplant + oncology testing + digital solutions at ≈81% blended gross margin.
• April 28 (same day as 10-Q) — agreed to acquire Naveris for $160M cash + up to $100M earnout on 2026-2027 revenue milestones. The 10-Q is silent on what Naveris does. Public sources: Naveris is a pure-play HPV-driven cancer MRD company; lead test NavDx detects TTMV-HPV ctDNA fragments for recurrence monitoring in oropharyngeal/anal/cervical cancers. ≈$34M 2025E revenue, guided 30-40% CAGR through 2028, 130,000+ tests run, ≈2,000 active ordering physicians, 400+ medical sites. ADLT designation April 2024 (CPT 0356U) at $1,800 Medicare. Last private mark ≈$75M (Gurnet Point Capital led).

Tightest possible technology adjacency to AlloSure: both circulating cell-free DNA assays, both ride MolDX/PAMA reimbursement pathway, both surveillance commercial models, same ddPCR-class chemistry. Deal multiple: 4.7x base / 7.6x ceiling on 2025E revenue. Earnout = 62% of base price = seller pricing in delivery of the 30-40% guide.

Qui tam dismissal (April 23). Private relator who filed False Claims Act suit in 2021 voluntarily dismissed; DOJ consented. DOJ already declined intervention October 2024; SEC closed investigation September 2023. Five-year DOJ/SEC/qui tam overhang fully cleared.

Bear items in the same filing.

• Refunds reserve doubled $3.5M → $7.95M; revenue reduced $3.4M for the increase. 10-Q discloses active dispute with "significant Medicare Advantage payer" over recoupment of previously paid claims. Total exposure unquantified.
• Draft LCD DL40058/DL40060 (issued July 17, 2025): bundled-payment concept for AlloSure surveillance, "could lead to fewer surveillance tests being reimbursed." 365-day finalization deadline → ~July 2026. Surveillance is 74% of testing revenue. PAMA amendment (Feb 2026) requires private-payer rate reporting May-July 2026; management guides minimal pricing impact.
• Nathan Smith executive separation Feb 25, 2026 — < 9 months after CIC and severance agreements signed May 2025. Role unclear from filing.
• G&A +34%, S&M +32%; combined opex $60.9M (vs $45.8M Q1 2025). New $3.4M "business development and portfolio optimization expense" line in segment reconciliation. SBC unrecognized $57.8M (≈9% latent dilution).
• AlloSure Kidney Medicare rate cut $88/test effective Jan 1, 2026 — absorbed in Q1 (gross margin expanded 570bps anyway via Medicare mix decline + lab efficiency); headwind continues.
• EPIC Aura: zero mention in Q1 2026 10-Q narrative despite Q3 2025 targets (≈10% testing volume by YE2025, ≈50% by YE2026). Patient & digital +33% attributed to "pharmacy" and "Ottr software." Soft contradiction of the moat narrative.

What the market thinks

Stock at ≈$19.50, up from ≈$15 pre-events. Mkt cap $1.0B, 51.3M shares. Pro-forma cash post-EuroBio/Naveris swap: ≈$208M. Zero debt. New $100M buyback authorization April 30. Sell-side coverage 6-8 analysts.

Setup: +33% trailing month — qui tam clearance and Q1 print broadly digested. RSI 66, ≈89% of 52-week range. ATM IV at 91st percentile — options market pricing a binary. Max pain ≈$17.50 — dealers positioned for a downside resolution.

Scenario EV (probabilities anchored to pred-6tlyvi 55% LCD finalized substantially intact):

Naive EV ≈ +0.5% with std dev ≈37%. Sensitivity: shifting LCD-favorable probability ±5pp moves EV from -3.4% to +4.4%. Edge on LCD outcome itself is approximately zero — the market is pricing the binary roughly correctly.

Sum-of-parts ignoring LCD risk: transplant core $1.48B at 4x FY26E rev + digital $280M + Naveris ≈$200M (4-5x on ≈$40M run-rate at YE26) + cash $208M ≈ $2.2B ≈ $42/share. After applying the scenario-weighted LCD haircut, risk-adjusted value lands near current price. The LCD discount accounts for essentially all of the gap to unimpaired SOTP. That's the mispricing question — not whether $42 is right, but whether the LCD haircut is right.

Why the gap exists

The reshape is real and idiosyncratic. Cross-checking peers — NTRA, VCYT, EXAS, GH most recent 10-Qs — none are doing comparable strategic surgery. CDNA's reshape is not a sector pattern. But the market cannot price the structural shift cleanly while the LCD binary dominates near-term variance. Three specific gaps remain in consensus:

1. Naveris strategic-framing layer. The basic acquisition facts are public via the April 28 press release and the +33% trailing-month rally reflects initial reaction. What's NOT yet broadly synthesized: the platform-fit argument (same MolDX/PAMA reimbursement pathway, same ddPCR chemistry, same surveillance commercial model as AlloSure), the ADLT-designation economics, and the deal-multiple framing (4.7x base / 7.6x ceiling on 2025E revenue is reasonable for an ADLT-protected MRD grower). Sell-side will close this layer over the next several earnings cycles. Less alpha here than the headline gap implies — incremental, not undiscovered.

2. Net-cash-neutral framing of the swap. $170M in / $160M out ≈ cash-neutral. CDNA paid for an oncology MRD growth asset by divesting a low-margin, declining product segment that diluted blended margins. The transformation isn't a balance-sheet event; it's a portfolio refactor. This framing isn't broadly out yet.

3. Q1 GAAP profit headline overstates organic. The $17.7M prior-period catch-up de-rates organic testing growth from 48% to ≈24%. Sell-side models that use the headline will face mechanical Q2 disappointment if the catch-up doesn't recur at scale.

What the market is correctly pricing: the LCD binary probability (≈50%, IV 91st percentile), the qui tam clearance (already moved), the rate cut absorption (broadly expected).

Risks (ranked)

1. Draft LCD finalization (~July 2026) with bundled-payment limitations substantially intact. ≈55% probability. Affects 74% of testing revenue. Multi-quarter compression, multiple compression, downside ≈$11-14. Dominates everything.
2. Medicare Advantage payer recoupment dispute scope. $7.95M reserve is a floor; ceiling unbounded. Could compress revenue per test 5-15% if recoupment is broad. Pending sector-vs-idio resolution via peer Q1 2026 prints.
3. Q1 organic revenue quality. If $17.7M prior-period catch-up doesn't recur, Q2 testing services normalizes to ≈$80M, below mechanical sell-side models.
4. EPIC Aura execution against YE2026 50% target. 10-Q narrative silence is a soft contradiction. If the moat thesis weakens, switching costs are lower than the FY2025 narrative implied.
5. Bio-Rad MyHPVScore competitive timing. RUO today, no Medicare. 18-36 month watch. Caps Naveris terminal upside if Bio-Rad pursues IVD aggressively.
6. Opex running hot, ≈9% SBC dilution overhang. $60.9M Q1 opex (+33% YoY); $3.4M new "business development and portfolio optimization expense" line. Tested by Q2 leverage as M&A transaction costs fade.
7. Nathan Smith executive departure < 9 months post-CIC — yellow flag pending role disclosure.

Catalysts

What would change our mind

Bullish updates:

• LCD withdrawn, substantively softened, or comment-period commentary signals retreat → near-full rerate to sum-of-parts; reshape alpha plus cleared overhang
• CEO Form 4 code P open-market buy at current levels → revises insider signal, bear floor narrows
• Pullback to $15-16 (50DMA, prior consolidation) before LCD → bear case partially priced; even pre-resolution EV improves
• Naveris first integrated print >40% growth → validates earnout structure thesis, derisks deal multiple

Bearish updates:

• Multiple peers (NTRA / VCYT / GH) disclose specific MA payer recoupment disputes → tag MA as sector beta, reframe MA payer overhang as broader industry headwind
• LCD finalization signals strict bundled-payment language → compression confirmed; reframe to distressed-asset thesis on $200M cash + Naveris
• Q2 testing services revenue <$80M → $17.7M catch-up was one-time, organic decelerates
• Continued EPIC Aura silence on Q3 2026 call → moat thesis degrades
• Bio-Rad files IVD on MyHPVScore inside 18 months → Naveris terminal value compresses

Evidence